National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 9/8/2006     First Published: 4/23/2004  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Study of Emotional Needs Among Caregivers of Post-Hematopoietic Stem Cell Transplantation Patients

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information
Registry Information

Alternate Title

Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

No phase specified


Educational/Counseling/Training


Closed


21 and over


NCI


FHCRC-1639.00
NCT00082654

Objectives

  1. Assess expression of emotion, as a function of patient presence, among spousal or other cohabiting caregivers (CG) of post-hematopoietic stem cell transplantation patients.
  2. Assess desynchrony among subjective (self-report) and expressive indicators of emotion, as a function of patient presence, in these participants.
  3. Correlate CG dispositional inhibition and desynchrony with physical and marital satisfaction in these participants.

Entry Criteria

Disease Characteristics:

  • In a marriage OR long-term, committed, heterosexual or homosexual, cohabiting relationship in which one member is post-hematopoietic stem cell transplantation
    • Patients must meet the following criteria:
      • At least 1 year since prior first bone marrow, stem cell, or umbilical cord blood transplantation
        • Allogeneic or autologous
      • Diagnosis of malignancy, myelodysplasia, or non-malignancy
      • No indication of possible or confirmed relapse
    • Spouse/caregiver (CG) must meet the following criteria:
      • Serve as the primary CG to the patient
      • No prior or concurrent neurologic disorder


Prior/Concurrent Therapy:

Biologic therapy

  • See Disease Characteristics

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Patient Characteristics:

Age

  • 21 and over

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Other

  • No concurrent major psychiatric disorder
  • English-speaking

Expected Enrollment

A total of 60 patient/spouse couples will be accrued for this study within 18 months.

Outline

Caregivers (CG) complete written questionnaires assessing demographics, positive and negative affect, dispositional inhibition, marital satisfaction, and physical health over 45 minutes to 1 hour on day 1. CG then engage in two oral emotional expression exercises (on the topic of caregiving and the transplant) over 2 hours on day 2. Patients are present for one oral emotional expression exercise.

Participants are followed at 2 weeks and 6 months.

Trial Contact Information

Trial Lead Organizations

Fred Hutchinson Cancer Research Center

Shelby Langer, PhD, Principal investigator
Ph: 206-667-5162

Registry Information
Official Title Emotional Needs of Caregivers and Patient/Spouse Couples During Hematopoietic Stem Cell Transplantation (HSCT)
Trial Start Date 2002-03-05
Registered in ClinicalTrials.gov NCT00082654
Date Submitted to PDQ 2004-01-28
Information Last Verified 2006-09-08
NCI Grant/Contract Number P30-CA15704, R03-CA96468

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov